Vedanta Biosciences
Vedanta Biosciences raises $108M Series D at $550M valuation
Quick Facts
Vedanta Biosciences: Series D Funding Round
Vedanta Biosciences has successfully raised $108M in Series D funding, reaching a valuation of $550M.
Company Overview
Microbiome-derived therapeutics
Funding Details
The Series D round was led by Johnson & Johnson Innovation, with participation from Mitsui & Co, Puretech Health, Flagship Pioneering.
Company Information
- Headquarters: 501 Boylston Street, Boston, MA 02116
- Founded: 2010
- Employees: 150+
- Category: Biotech
Investment
Vedanta Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Johnson & Johnson Innovation: Verified investor in Series D
- Mitsui & Co: Verified investor in Series D
- Puretech Health: Verified investor in Series D
- Flagship Pioneering: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...